Mylan Inc (MYL) 72.40 $MYL Will Teva Manage To Complete

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:36 PM

Mylan Inc (MYL) 72.40 $MYL

Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - 1 hr 51 mins ago

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09)

Don't Cash In On Perrigo Yet, Upside Still Possible
Value Hawk - Seeking Alpha - 2 hrs 8 mins ago
Summary: We recommend a sell for Perrigo Company (NYSE: PRGO ) with two triggers based on the possible scenarios. First, if Perrigo's price falls to $185, we recommend selling to protect significant gains from recent M&A conversations. On the...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), MYL: 72.40 (-1.67)

Concerns About Soaring Generic Prices Could Present Teva With Ultimate Challenge
EP Vantage - Seeking Alpha - Wed Apr 22, 11:31AM CDT
That Teva (NYSE: TEVA ) would declare its interest in Mylan (NASDAQ: MYL ) was a foregone conclusion. The consummation of any such deal is far from certain. An agreement on price would probably get investors in both camps on board, but these are...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Stock Market News for April 22, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Benchmarks finished Tuesday’s trading session mostly lower following a mixed bag of earnings reports
VRTX: 132.85 (+0.65), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), MYL: 72.40 (-1.67), AMGN: 169.10 (+0.64), XOM: 87.46 (+0.58), SLB: 92.16 (+0.87), RIG: 16.85 (-0.18), IBM: 165.36 (+1.10), EOG: 97.70 (+1.11), DD: 71.44 (+0.75), TEVA: 63.01 (-1.15), CVX: 109.50 (-0.23), REGN: 472.63 (+9.41), TRV: 102.02 (+0.14)

Mylan preparing new bid for Perrigo
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:47AM CDT

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan
at The Street - Wed Apr 22, 8:46AM CDT
Teva has a path to complete the deal.
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Critical Alerts For Celgene, Rambus, Mylan, Amgen and Zoetis Released By InvestorsObserver
PR Newswire - Wed Apr 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, RMBS, MYL, AMGN and ZTS.
ZTS: 47.03 (-0.51), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), RMBS: 14.40 (+0.22), CELG: 115.54 (+0.72)

Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:00AM CDT
Perrigo Company's third-quarter fiscal 2015 earnings of $1.85 per share beat the Zacks Consensus Estimate of $1.80.
BIIB: 423.57 (+1.46), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
ENZN: 1.70 (+0.20), HLF: 46.63 (-0.13), VSI: 44.50 (+5.54), GNC: 47.56 (+1.60), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
Business Wire - Wed Apr 22, 7:30AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) today announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (NASDAQ: MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Teva's proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion.
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Upgrade Alert for Mylan (MYL)
Comtex SmarTrend(R) - Wed Apr 22, 7:11AM CDT
Mylan (NASDAQ:MYL) was upgraded from Underperform to Market Perform at BMO Capital today. The stock closed yesterday at $74.07 on volume of 42.3 million shares, above average daily volume of 10.4 million. Based on a current price of $74.07, Mylan is currently 15.7% above its average consensus analyst price target of $62.44. The stock should find initial support at its 50-day moving average (MA) of $60.20 and further support at its 200-day MA of $53.86.
MYL: 72.40 (-1.67)

Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)

Wall Street Breakfast: China Shares Extend Bull Run
Wall Street Breakfast - at Seeking Alpha - Wed Apr 22, 5:30AM CDT

PRGO: 201.50 (+8.68), BX: 41.76 (+0.04), SNE: 32.35 (+1.47), GOOG: 539.36 (+5.39), NOV: 53.93 (+0.80), YHOO: 43.97 (-0.52), SPY: 210.63 (+1.03), RIG: 16.85 (-0.18), S: 5.08 (+0.10), CMG: 641.23 (-51.29), FOXA: 34.04 (+0.09), GOOGL: 549.18 (+6.26), TMUS: 34.09 (+0.74), TWC: 149.64 (-2.36), MYL: 72.40 (-1.67), DIS: 107.94 (+0.26), PXD: 172.93 (-0.64), QQQ: 108.65 (+0.59), ARMH: 54.07 (+0.47), TEVA: 63.01 (-1.15), VZ: 49.57 (+0.40), CMCSA: 58.76 (-0.08), EPD: 33.35 (-0.29)

Reuters: Top Mylan shareholders seek deal with Teva
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 2:01AM CDT

MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Update - Perrigo's Rejection Of Offer Gives Mylan 5 Strategy Options
Jordan Flannery - at Seeking Alpha - Tue Apr 21, 11:01PM CDT

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)

Perrigo unanimously rejects Mylan bid
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:53PM CDT

PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67)

Watch for Mylan to Potentially Pullback After Gaining 8.85% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 3:45PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $72.99 to a high of $74.90. Yesterday, the shares gained 8.9%, which took the trading range above the 3-day high of $72.16 on volume of 42.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 72.40 (-1.67)

Look for Shares of Mylan to Potentially Pullback after Yesterday's 8.85% Rise
Comtex SmarTrend(R) - Tue Apr 21, 3:44PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $72.99 to a high of $74.90. Yesterday, the shares gained 8.9%, which took the trading range above the 3-day high of $72.16 on volume of 42.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 72.40 (-1.67)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...